Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px

Document › Details

Biocartis Group N.V.. (1/23/19). "Press Release: Biocartis Successfully Raises EUR 55.50 Milion in an Equity Placement [NOT FOR US, AU, CA, JP, ZA, et al.]". Mechelen.

	Organisation	Biocartis Group N.V. (Euronext Brussels: BCART)
	Group	Biocartis (Group)
	Organisation 2	Kempen & Co. N.V.
	Group	Van Lanschot (Group)
	Product	Idylla™ molecular diagnostics system
	Product 2	investment banking
	Index term	Biocartis–SEVERAL: investment, 201901 private placement €55.5m of 5m new shares at €11.1/share
	Person	Welten, Ewoud (Biocartis 201607 CFO)
	Person 2	Degrave, Renate (Biocartis 201611 Manager CorpComm + IR)

Original document
accessed by [iito] on 2018-01-23

Record changed: 2019-02-03

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for Biocartis (Group)

[1] Biocartis Group N.V.. (6/1/19). "Press Release: Biocartis and Kite Sign Agreement for Development of Assays Supporting Kite's Therapies". Mechelen....
[2] Biocartis Group N.V.. (4/25/19). "Press Release: Biocartis Q1 2019 Business Update". Mechelen....
[3] Biocartis Group N.V.. (4/23/19). "Press Release: Biocartis Announces Global Collaboration with Covance". Mechelen....
[4] Biocartis Group N.V.. (1/23/19). "Press Release: Biocartis Upsizes Its Equity Placement Due to Significant Demand [NOT FOR US, AU, CA, JP, ZA, et al.]". Mechelen....
[5] Biocartis Group N.V.. (1/23/19). "Press Release: Biocartis Launches Equity Placement [NOT FOR US, AU, CA, JP, ZA, et al.]". Mechelen....
[6] Biocartis Group N.V.. (12/3/18). "Press Release: Genomic Health and Biocartis Expand Collaboration to Urology with the Development of an Idylla Oncotype DX Genomic Prostate Score Test". Redwood City, CA & Mechelen....
[7] Biocartis Group N.V.. (11/29/18). "Press Release: Biocartis and AstraZeneca Enter into Agreement Aimed at Faster Lung Cancer Biomarker Results". Mechelen....
[8] Biocartis Group N.V.. (9/3/18). "Press Release: Biocartis and Wondfo Announce Joint Venture for Commercialization of Idylla Platform in China". Mechelen & Guangzhou....
[9] Biocartis Group N.V.. (8/28/18). "Press Release: Biocartis Obtains Exclusive Worldwide License Rights for EGFR Ectodomain Mutations Determining Response to Targeted Colorectal Cancer Therapy". Mechelen....
[10] Biocartis Group N.V.. (7/17/18). "Press Release: Biocartis Launches Innovative Idylla MSI Assay". Mechelen....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

» top